PKC-independent modulation of multidrug resistance in cells with mutant (V185) but not wild-type (G185) P-glycoprotein by bryostatin 1

Biochemical Pharmacology

Volumn 56, Issue 7, 1998, Pages 861-869

  Spitaler, Martin ^a   Utz, Irene ^a   Hilbe, Wolfgang ^b   Hofmann, Johann ^a   Grunicke, Hans H ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Bryostatin 1; Multidrug resistance; P glycoprotein; Protein kinase C; Reversal; Rhodamine 123

Indexed keywords

ANTINEOPLASTIC AGENT; BRYOSTATIN 1; GLYCOPROTEIN P; PROTEIN KINASE C; RHODAMINE 123;

ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AMINO ACID SUBSTITUTION; BINDING, COMPETITIVE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HELA CELLS; HUMANS; KB CELLS; LACTONES; MACROLIDES; P-GLYCOPROTEIN; POINT MUTATION; PROTEIN KINASE C;

EID: 0032190505     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00107-5     Document Type: Article

References (41)

1. Pettit G.R. The bryostatins. Progr Chem Org Nat Prod. 57:1991;153-195.
2. Dale I.L., Gescher A. Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells. Int J Cancer. 43:1989;158-163.
3. Kennedy M.J., Prestigiacomo L.J., Tyler G., May W.S., Davidson N.E. Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res. 52:1992;1278-1283.
4. Prendiville J., Crowther D., Thatcher N., Woll P.J., Fox B.W., McGown A., Testa N., Stern P., McDermott R., Potter M., Pettit G.R. A phase I study of i.v. bryostatin 1 in patients with advanced cancer. Br J Cancer. 68:1993;418-424.
5. 3H]bryostatin 4 to protein kinase C. Biochem Pharmacol. 43:1992;2007-2014.
6. Kraft A.S., Smith J.B., Berkow R.L. Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc Natl Acad Sci USA. 83:1986;1334-1338.
7. Jetten A.M., George M.A., Pettit G.R., Rearick J.I. Effects of bryostatins and retinoic acid on phorbol ester- and diacylglycerol-induced squamous differentiation in human tracheobronchial epithelial cells. Cancer Res. 49:1989;3990-3995.
8. Hocevar B.A., Fields A.P. Selective translocation of beta II-protein kinase C to the nucleus of human promyelocytic (HL60) leukemia cells. J Biol Chem. 266:1991;28-33.
9. Blumberg P.M. Complexities of the protein kinase C pathway. Mol Carcinog. 4:1991;339-344.
10. Isakov N., Galron D., Mustelin T., Pettit G.R., Altman A. Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase. J Immunol. 150:1993;1195-1204.
11. Sako T., Ohshima S., Yoshizumi T., Sakurai M. Differential modulation of protein kinase C by bryostatin 1 and phorbol ester. Tohoku J Exp Med. 156:1988;229-236.
12. Szallasi Z., Smith C.B., Pettit G.R., Blumberg P.M. Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts. J Biol Chem. 269:1994;2118-2124.
13. Endicott J.A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 58:1989;137-171.
14. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 62:1993;385-427.
15. Germann U.A., Chambers T.C., Ambudkar S.V., Pastan I., Gottesman M.M. Effects of phosphorylation of P-glycoprotein on multidrug resistance. J Bioenerg Biomembr. 27:1995;53-61.
16. Fine R.L., Patel J., Chabner B.A. Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA. 85:1988;582-586.
17. Posada J., Vichi P., Tritton T.R. Protein kinase C in adriamycin action and resistance in mouse sarcoma 180 cells. Cancer Res. 49:1989;6634-6639.
18. O'Brian C.A., Fan D., Ward N.E., Seid C., Fidler I.J. Level of protein kinase C activity correlates directly with resistance to adriamycin in murine fibrosarcoma cells. FEBS Lett. 246:1989;78-82.
19. Chambers T.C., McAvoy E.M., Jacobs J.W., Eilon G. Protein kinase C phosphorylates P-glycoprotein in multidrug-resistant human KB carcinoma cells. J Biol Chem. 265:1990;7679-7686.
20. Yu G., Ahmad S., Aquino A., Fairchild C.R., Trepel J.B., Ohno S., Suzuki K., Tsuruo T., Cowan K.H., Glazer R.I. Transfection with protein kinase C alpha confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun. 3:1991;181-189.
21. Gravitt K.R., Ward N.E., Fan D., Skibber J.M., Levin B., O'Brian C.A. Evidence that protein kinase C-α activation is a critical event in phorbol ester-induced multiple drug resistance in human colon cancer cells. Biochem Pharmacol. 48:1994;375-381.
22. Ahmad S., Glazer R.I. Expression of the antisense cDNA for protein kinase C alpha attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol Pharmacol. 43:1993;858-862.
23. Hofmann J., Gekeler V., Ise W., Noller A., Mitterdorfer J., Hofer S., Utz I., Gotwald M., Boer R., Glossmann H., Grunicke H. Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance. Biochem Pharmacol. 49:1995;603-609.
24. Smith C.D., Zilfou J.T. Circumvention of P-glycoprotein-mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. J Biol Chem. 270:1995;28145-28152.
25. Budworth J., Davis R., Malkhandi J., Gant T.W., Ferry D.R., Gescher A. Comparison of staurosporine and four analogs their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells . Br J Cancer. 73:1996;1063-1068.
26. Goodfellow H.R., Sardini A., Ruetz S., Callaghan R., Gros P., McNaughton P.A., Higgins C.F. Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein. J Biol Chem. 271:1996;13668-13674.
27. Gekeler V., Boer R., Überall F., Ise W., Schubert C., Utz I., Hofmann J., Sanders K.H., Schächtele C., Klemm K., Grunicke H. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203× on P-glycoprotein-mediated multidrug resistance. Br J Cancer. 74:1996;897-905.
28. Germann U.A., Chambers T.C., Ambudkar S.V., Licht T., Cardarelli C.O., Pastan I., Gottesman M.M. Characterization of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem. 217:1996;1708-1716.
29. Scala S, Dickstein B, Regis J, Szallasi Z, Blumberg PM, and Bates SE, Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells. Clinical Cancer Res 1: 15851-1587, 1995.
30. Akiyama S., Fojo A., Hanover J.A., Pastan I., Gottesman M.M. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somatic Cell Mol Genet. 11:1985;117-126.
31. Kimmig A., Gekeler V., Neumann M., Frese G., Handgretinger R., Kardos G., Diddens H., Niethammer D. Susceptibility of multidrug-resistant human leukemia cell lines to human interleukin 2-activated killer cells. Cancer Res. 50:1990;6793-6799.
32. Kane S.E., Reinhard D.H., Fordis M.C., Pastan I., Gottesman M.M. A new vector using the human multidrug resistance gene as a selectible marker enables over-expression of foreign genes into eukaryotic cells. Gene. 84:1989;439-446.
33. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 82:1990;1107-1112.
34. Hofmann J., Wolf A., Spitaler M., Böck G., Drach J., Ludescher C., Grunicke H. Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine. J Cancer Res Clin Oncol. 118:1992;361-366.
35. Hamada H., Tsuruo T. Purification of 170-180kDa membrane P-glycoprotein associated with multidrug resistance. J Biol Chem. 263:1988;1454-1458.
36. Noonan K.E., Beck C., Holzmayer T.A., Chin J.E., Wunder J.S., Andrulis I.L., Gazdar A.F., Willman C.L., Griffith B., Von Hoff D.D., Roninson I.B. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by PCR. Proc Natl Acad Sci USA. 87:1990;7160-7164.
37. Choi K., Chen C., Kriegler M., Roninson I.B. An altered pattern of cross-resistance in multidrug resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene. Cell. 53:1988;519-529.
38. Safa A.R., Stern K.R., Choi K., Agresti M., Tamai I., Mehta N.D., Roninson I.B. Molecular basis of preferential resistance to colchicine in multidrug resistant human cells conferred by Gly-185-Val-185 substitution in P-glycoprotein. Proc Natl Acad Sci USA. 87:1990;7225-7229.
39. Cardarelli C.O., Aksentijevich I., Pastan I., Gottesman M.M. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters. Cancer Res. 55:1995;1086-1091.
40. Gottesman M.M., Germann U.A., Aksentijevich I., Sugimoto Y., Cardarelli C.O., Pastan I. Gene transfer of drug resistance genes. Implications for cancer therapy. Ann NY Acad Sci. 716:1994;126-139.
41. Baudard M., Pastan I., Gottesman M.M. Transfer of the MDR1 gene into haematopoietic cells. Eur J Cancer. 32A:1996;1019-1023.